Table 1.
Summary of experimental design and vaccines.
| Experimental group | Vaccine (description/mutant insertion site) | Treatment |
|---|---|---|
| Group 1 (10 kids) | Negative control (Sham vaccine) | Sham-vaccinated, unchallenged |
| Group 2 (10 kids) | Control vaccine (Silirum0® vaccine) | Vaccinated, challenged |
| Group 3 (10 kids) | 316 vaccine (between MAP3695 and FadE5)* | Vaccinated, challenged |
| Group 4 (10 kids) | 315 vaccine (MAP1566)* | Vaccinated, challenged |
| Group 5 (10 kids) | 319 vaccine (MAP1566)* | Vaccinated, challenged |
| Group 6 (10 kids) | 318 vaccine (between MAP0282c and MAP0283c)* | Vaccinated, challenged |
| Group 7 (10 kids) | 329 vaccine (fabG2_2)** | Vaccinated, challenged |
| Group 8 (10 kids) | Positive control (Sham vaccine) | Sham-vaccinated, challenged |
*
Raúl G. Barletta mutant vaccine strains derived from K-10 by mutagenesis with IS1096 derived transposons.
**
Adel M. Talaat mutant vaccine strain (Shin et al., 2006).